← Back to signals
ROIV
LONGINSIDER SELLROIVANT SCIENCES LTD
Funds
4
Score
5.00
vs SPY
-8.1%
Stock return (since Q-end)
+8.3%
SPY return (since Q-end)
+16.3%
Current price
$29.99
News Summary
PositiveRoivant delivered a major earnings beat driven by a transformational $2.25B Moderna litigation settlement ($770M gain recognized in Q4), providing $950M upfront cash inflow in July 2026 and bolstering an already fortress balance sheet ($4.3B cash, no debt). However, underlying operational performance remains weak with revenue down 66.7% YoY, operating EPS miss (-$0.46 vs -$0.38 est.), and continued losses projected through FY2027, raising questions about sustainable profitability despite near-term cash windfalls.
Red flags
- •Revenue declined 66.7% year-over-year to $2.52M, significantly below expectations
- •Operating loss of $0.46 per share missed guidance of -$0.38, indicating operational deterioration
- •Q4 EPS beat ($0.28 vs -$0.29 est.) was heavily dependent on one-time litigation settlement gain rather than core business performance
- •Company projecting continued losses through at least H1 FY2027 (-$0.28 and -$0.30 EPS guidance)
- •Critical drug approval contingent on FDA action: brepocitinib dermatomyositis launch expected by end-September 2026 (regulatory risk)
- •Phase 3 batoclimab program for thyroid eye disease failed, representing pipeline setback
- •Litigation proceeds funding $1.5B share repurchase program rather than R&D investment, suggesting limited organic growth opportunities
Funds Buying (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | QoQ | Status |
|---|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | 6.7M | +209K | $184.3B | +3% | Existing |
| Greenlight Capital | David Einhorn | 2.2M | +83K | $59.6B | +4% | Existing |
| Maverick Capital | Lee Ainslie | 1.6M | +1.6M | $45.1B | — | NEW |
| Point72 | Steve Cohen | 891K | +891K | $24.7B | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed |
|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO | SELL | 200K | $30.27 | $6.05M | 2026-05-22 |
| Venker Eric | President & Immunovant CEO | SELL | 200K | $29.59 | $5.92M | 2026-04-20 |
| Gline Matthew | CEO | SELL | 290K | $29.16 | $8.45M | 2026-04-16 |
| Humes Jennifer | Chief Accounting Officer | SELL | 14K | $28.37 | $0.38M | 2026-04-08 |